TSW
ALDX icon

Thompson Siegel & Walmsley’s Aldeyra Therapeutics ALDX Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-27,000
Closed -$244K – 741
2019
Q1 		$244K Buy
+27,000
New +$229K ﹤0.01% 380

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Siegel & Walmsley's ALDX Position: Q2 2019 in Review

Thompson Siegel & Walmsley sold out of Aldeyra Therapeutics (ALDX) in Q2 2019, closing a stake of 27,000 shares — an estimated $244K sold.

Thompson Siegel & Walmsley first reported a position in ALDX in Q1 2019 and held it in 1 quarter. The position peaked at $244K in Q1 2019. 76 funds tracked by Wall St. Rank hold ALDX as of Q2 2019.

  • Thompson Siegel & Walmsley reported no remaining Aldeyra Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 27,000 Aldeyra Therapeutics shares in Q2 2019, an estimated $244K.
  • Thompson Siegel & Walmsley first reported a position in Aldeyra Therapeutics in Q1 2019 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Aldeyra Therapeutics position peaked at $244K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2019.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2019, filed 12 Aug 2019.